idarubicin (NanoMed)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameidarubicin (NanoMed)
Drug Alias Nameidarubicinidarubicin NPidarubicin (NanoMed)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA intercalators
TargetsDNA
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNanomed Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanomed Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A